MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Troxerutin

CAS No. : 7085-55-4

MCE 站：Troxerutin

产品活性：Troxerutin 也被称为维生素 P4，是天然生物类黄酮芦丁的三羟乙基化衍生物，其可抑制活性氧 (ROS) 的产生并抑制 ER 应激介导的 NOD 活化。

研究领域：Immunology/Inflammation

作用靶点：NOD-like Receptor (NLR)

In Vitro: The results reveal that the maximum protective effect against ROS induced cell damage in the HDP cells occurs following pretreatment with 10 μM Troxerutin. Treatment with H₂O₂ alone decreases cell viability to 77.33±2.44%; however, pretreatment with 10 μM Troxerutin maintains cell viability at 90.88±2.24% following H₂O₂ exposure (P<0.05). At concentrations of 5 and 10 μM, pretreatment with Troxerutin causes a decrease in the number of cells in the sub G1 phase, indicative of cell death. In the control and Troxerutin-only-treated cells, 3.58±0.15 and 0.89±0.11% are 2′7′-dichlorofluorescein (DCF)-positive (P<0.05), whereas treatment with H₂O₂ alone increases the level of ROS to 46.36±2.33%. The cells pretreated with Troxerutin are 19.92±1.95% DCF-positive following H₂O₂ treatment, indicating that Troxerutin reduces the H₂O₂-induced production of ROS in the HDP cells .

In Vivo: Troxerutin effectively lowers body weight and obesity-related metabolic parameters in high-fat diet (HFD)-treated mice. Oral administration of Troxerutin notably inhibits those liver injuries in HFD-treated mice, restores glucose intolerance and insulin signaling, and diminishes hepatic gluconeogenesis in HFD-treated mice. Troxerutin remarkably inhibits the nuclear translocation of NF-κB p65, as well as the expressions of its target genes, in the livers of HFD-treated mice. Troxerutin also depresses endoplasmic reticulum (ER) stress-mediated Nucleotide oligomerization domain (NOD) activation in HFD-treated mouse livers. Lipid depositions in tunica intimae and tunica media are attenuated in Troxerutin-treated diabetic rats compare with untreated diabetic rats. Structural disarrangement and deformity of smooth muscle cells in aortic tissue of Troxerutin-treated diabetic rats are considerably lower than histology of untreated diabetic aorta. Administration of Troxerutin for four weeks to diabetic rats significantly reduces the level of malondialdehyde (MDA) compare to that of untreated diabetic rats (P<0.01).

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  NF-κB Signaling Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Antioxidants Compound Library  |  Diabetes Related Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Endoplasmic Reticulum Stress Compound Library  |  Pyroptosis Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Flavonoids Library  |  MCC950 sodium  |  Nigericin sodium salt  |  CY-09  |  Dapansutrile  |  Stavudine  |  Muscone  |  INF39  |  Nodinitib-1  |  Trimethylamine N-oxide  |  NOD-IN-1  |  Ruscogenin  |  GSK717  |  NLRP3-IN-2  |  Cardamonin  |  Arglabin  |  YQ128  |  CORM-3  |  JC-171  |  Soyasaponin II

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。